IPO

Innova Captab's IPO offers ₹320 crore in fresh shares and ₹250 crore in existing share sales. Funds will aid loan repayments, UML investment, and company operations.

[{"selector":"#anim-bf02720e-dbdd-45c5-a2f6-02ebc625bd83","keyframes":{"opacity":[1,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-3db3fff7-b077-465e-932e-a90fa7e13e2f","keyframes":{"transform":["scale(3)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-5aac469c-be7c-42d6-a220-ea56ebb19454","keyframes":{"opacity":[0,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-055a3fa7-dd58-4675-9de0-b997aec5dd61","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] Brush Stroke Read more

IPO Date: Dec 21 to Dec 26, 2023 IPO Listing Date: Dec 29, 2023 IPO Price: INR 426 to INR 448 per share IPO Lot Size: 33 Shares IPO Total Issue Size: INR 570 crores

[{"selector":"#anim-24c07e9b-6aa8-4c9c-9456-175a3d6c99cf","keyframes":{"opacity":[1,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-c00eb044-2ff2-4e71-ade6-dc051d058c41","keyframes":{"transform":["scale(3)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-f0fb8754-833a-46e0-8b65-7b8c3e41e2cc","keyframes":{"opacity":[0,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-efbed9a9-c551-409c-9f61-0cfd41f2c2ef","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] Brush Stroke Important Dates

Innova Captab IPO flaunts sales growth, higher investments, and asset value. Despite expenses, it lures investors with increased revenue and asset allure.

[{"selector":"#anim-9bb8ddfa-d1c0-4352-8c24-55024ca4a2f2","keyframes":{"opacity":[1,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-34198e24-7560-49d2-813e-052646608433","keyframes":{"transform":["scale(3)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-e42d86ae-f47b-4107-ad51-8eb81f47421c","keyframes":{"opacity":[0,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-1484c957-7edb-4a40-b710-fd3b0ee491a1","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] Brush Stroke Fundamental Analysis

Innova Captab boasts strong revenue, EPS, RoNW, and moderate P/E. Torrent Pharma and Ajanta Pharma lead in revenue and EPS, while Windlas Biotech exhibits a lower P/E ratio among peers.

[{"selector":"#anim-9730a087-f943-42f2-adac-1f727e9084a5","keyframes":{"opacity":[1,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-8252da9e-5c5c-4382-8027-e372e193ad99","keyframes":{"transform":["scale(3)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-41021228-71b8-4946-ba42-f5c38d834ccb","keyframes":{"opacity":[0,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-075c7405-fbc3-4edb-b5c7-2bdb808be0d0","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] Brush Stroke Peer Comparison

Innova Captab allocates INR 144 Cr for loan repayment, INR 23.60 Cr for subsidiary, INR 72 Cr for working capital, and the rest for general corporate needs for growth and unforeseen expenses.

[{"selector":"#anim-9675b545-335c-4e36-8fcf-4bf1ab387b6a","keyframes":{"opacity":[1,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-97dd3e35-f73e-4a50-8f19-88bedcba320d","keyframes":{"transform":["scale(3)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-33b9710b-15bb-4024-a004-859fc28bca1e","keyframes":{"opacity":[0,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-8005fa61-4ccf-47e2-8434-4bb059fddd3f","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] Brush Stroke Obective

Innova Captab faces manufacturing risks and competes in the dynamic CDMO sector. Evolving healthcare needs adaptability amid regulatory reforms and price controls.

[{"selector":"#anim-e93bd92f-ef7a-4cc2-8772-f59614ee9f70","keyframes":{"opacity":[1,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-e18a401b-0e43-4708-8abb-c0e58176cc45","keyframes":{"transform":["scale(3)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-cdad4aa2-5650-46af-83ba-f38484071e47","keyframes":{"opacity":[0,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-bc745141-3de9-4e89-ab97-cc203bd212b4","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] Brush Stroke Risks and Challenges

Apply for Innova Captab IPO - with Alice Blue Completely Free of Cost.

[{"selector":"#anim-92264bd1-ea2f-4c03-ad9a-eb323672e8cf","keyframes":{"opacity":[1,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-fe99eb21-c0e2-4394-b4ef-1f8f5d69546b","keyframes":{"transform":["scale(3)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-71802eea-bbe8-4002-acd2-5fc8b7d843a3","keyframes":{"opacity":[0,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-e754722c-4f1a-438f-98b9-52e0b2d87cd8","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] Brush Stroke Open Account Now!!

IPO

Innova Captab's IPO offers ₹320 crore in fresh shares and ₹250 crore in existing share sales. Funds will aid loan repayments, UML investment, and company operations.

Innova Captab IPO

IPO Date: Dec 21 to Dec 26, 2023 IPO Listing Date: Dec 29, 2023 IPO Price: INR 426 to INR 448 per share IPO Lot Size: 33 Shares IPO Total Issue Size: INR 570 crores

Important Dates

Innova Captab IPO flaunts sales growth, higher investments, and asset value. Despite expenses, it lures investors with increased revenue and asset allure.

Fundamental Analysis

Innova Captab boasts strong revenue, EPS, RoNW, and moderate P/E. Torrent Pharma and Ajanta Pharma lead in revenue and EPS, while Windlas Biotech exhibits a lower P/E ratio among peers.

Peer Comparison

Innova Captab allocates INR 144 Cr for loan repayment, INR 23.60 Cr for subsidiary, INR 72 Cr for working capital, and the rest for general corporate needs for growth and unforeseen expenses.

Objective

Innova Captab faces manufacturing risks and competes in the dynamic CDMO sector. Evolving healthcare needs adaptability amid regulatory reforms and price controls.

Risks And Challenges

Apply for Innova Captab IPO - with Alice Blue Completely Free of Cost.